Daiichi Sankyo takes oncology shift into next phase with new global business unit

Daiichi Sankyo is taking another big step in its transformation to oncology drugmaker. The pharma company recently laid out plans to create an integrated oncology business unit, tapping current U.S. business chief Ken Keller to take the reins when it opens its doors on April 1.